Aztreonam (Indonesian Wikipedia)
Analysis of information sources in references of the Wikipedia article "Aztreonam" in Indonesian language version.
refsWebsite
Global rank
Indonesian rank
1st place
1st place
6th place
2nd place
102nd place
411th place
low place
low place
5,225th place
low place
712th place
389th place
5th place
7th place
3rd place
6th place
archive.org
- British national formulary : BNF 69 (edisi ke-69). British Medical Association. 2015. hlm. 381. ISBN 9780857111562.
- Johnson DH, Cunha BA (1995). "Aztreonam". Medical Clinics of North America (dalam bahasa Inggris). 79 (4): 733–743. doi:10.1016/S0025-7125(16)30036-0
. PMID 7791420.
books.google.com
- Yaffe SJ, Aranda JV (2010). Neonatal and Pediatric Pharmacology: Therapeutic Principles in Practice. Lippincott Williams & Wilkins. hlm. 438. ISBN 9780781795388.
businessweek.com
- Catherine L (22 February 2010). "Gilead's Inhaled Antibiotic for Lungs Wins Approval". BusinessWeek. Diarsipkan dari versi asli tanggal 2 March 2010. Diakses tanggal 5 March 2010.
- "FDA approves Gilead cystic fibrosis drug Cayston". BusinessWeek. 23 February 2010. Diarsipkan dari versi asli tanggal 1 March 2010. Diakses tanggal 5 March 2010.
clinicaltrials.gov
- Nomor uji klinis NCT03329092 for "A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria. (REVISIT)" di ClinicalTrials.gov
- Nomor uji klinis NCT03580044 for "Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria" di ClinicalTrials.gov
doi.org
- Quon BS, Goss CH, Ramsey BW (March 2014). "Inhaled antibiotics for lower airway infections". Annals of the American Thoracic Society. 11 (3): 425–34. doi:10.1513/annalsats.201311-395fr. PMC 4028738 . PMID 24673698.
- Kobayashi Y, Uchida H, Kawakami Y (December 1992). "Synergy with aztreonam and arbekacin or tobramycin against Pseudomonas aeruginosa isolated from blood". The Journal of Antimicrobial Chemotherapy. 30 (6): 871–2. doi:10.1093/jac/30.6.871. PMID 1289363.
- James CW, Gurk-Turner C (January 2001). "Cross-reactivity of beta-lactam antibiotics". Proceedings. 14 (1): 106–107. doi:10.1080/08998280.2001.11927741. PMC 1291320 . PMID 16369597.
- Johnson DH, Cunha BA (1995). "Aztreonam". Medical Clinics of North America (dalam bahasa Inggris). 79 (4): 733–743. doi:10.1016/S0025-7125(16)30036-0 . PMID 7791420.
- Mauri C, Maraolo AE, Di Bella S, Luzzaro F, Principe L (August 2021). "The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases". Antibiotics. 10 (8): 1012. doi:10.3390/antibiotics10081012 . PMC 8388901 Periksa nilai
|pmc=(bantuan). PMID 34439062 Periksa nilai|pmid=(bantuan). - Di Bella S, Sanson G, Monticelli J, Zerbato V, Principe L, Giuffrè M, Pipitone G, Luzzati R (February 2024). Staley C, Abhyankar M, ed. "Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options". Clinical Microbiology Reviews: e0013523. doi:10.1128/cmr.00135-23. PMID 38421181 Periksa nilai
|pmid=(bantuan). - Terico AT, Gallagher JC (December 2014). "Beta-lactam hypersensitivity and cross-reactivity". Journal of Pharmacy Practice. 27 (6): 530–544. doi:10.1177/0897190014546109 . PMID 25124380.
drugs.com
- "Aztreonam". The American Society of Health-System Pharmacists. Diakses tanggal 8 December 2017.
handle.net
hdl.handle.net
- World Health Organization (2019). Executive summary: the selection and use of essential medicines 2019: report of the 22nd WHO Expert Committee on the selection and use of essential medicines. Geneva: World Health Organization. hdl:10665/325773 . WHO/MVP/EMP/IAU/2019.05. License: CC BY-NC-SA 3.0 IGO.
- World Health Organization (2019). The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl:10665/330668 . ISBN 9789241210300. ISSN 0512-3054. WHO technical report series;1021.
nih.gov
ncbi.nlm.nih.gov
- Quon BS, Goss CH, Ramsey BW (March 2014). "Inhaled antibiotics for lower airway infections". Annals of the American Thoracic Society. 11 (3): 425–34. doi:10.1513/annalsats.201311-395fr. PMC 4028738 . PMID 24673698.
- Kobayashi Y, Uchida H, Kawakami Y (December 1992). "Synergy with aztreonam and arbekacin or tobramycin against Pseudomonas aeruginosa isolated from blood". The Journal of Antimicrobial Chemotherapy. 30 (6): 871–2. doi:10.1093/jac/30.6.871. PMID 1289363.
- James CW, Gurk-Turner C (January 2001). "Cross-reactivity of beta-lactam antibiotics". Proceedings. 14 (1): 106–107. doi:10.1080/08998280.2001.11927741. PMC 1291320 . PMID 16369597.
- Johnson DH, Cunha BA (1995). "Aztreonam". Medical Clinics of North America (dalam bahasa Inggris). 79 (4): 733–743. doi:10.1016/S0025-7125(16)30036-0 . PMID 7791420.
- Mauri C, Maraolo AE, Di Bella S, Luzzaro F, Principe L (August 2021). "The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases". Antibiotics. 10 (8): 1012. doi:10.3390/antibiotics10081012 . PMC 8388901 Periksa nilai
|pmc=(bantuan). PMID 34439062 Periksa nilai|pmid=(bantuan). - Di Bella S, Sanson G, Monticelli J, Zerbato V, Principe L, Giuffrè M, Pipitone G, Luzzati R (February 2024). Staley C, Abhyankar M, ed. "Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options". Clinical Microbiology Reviews: e0013523. doi:10.1128/cmr.00135-23. PMID 38421181 Periksa nilai
|pmid=(bantuan). - Terico AT, Gallagher JC (December 2014). "Beta-lactam hypersensitivity and cross-reactivity". Journal of Pharmacy Practice. 27 (6): 530–544. doi:10.1177/0897190014546109 . PMID 25124380.
toku-e.com
- "Aztreonam Susceptibility and Minimum Inhibitory Concentration (MIC) Data" (PDF). toku-e.com. 3 February 2020.
- "Aztreonam spectrum of bacterial susceptibility and Resistance" (PDF). Product Data Sheet. toku-e.com. Diarsipkan dari versi asli (PDF) tanggal 27 March 2014. Diakses tanggal 15 May 2012.
web.archive.org
- "Aztreonam spectrum of bacterial susceptibility and Resistance" (PDF). Product Data Sheet. toku-e.com. Diarsipkan dari versi asli (PDF) tanggal 27 March 2014. Diakses tanggal 15 May 2012.
- Catherine L (22 February 2010). "Gilead's Inhaled Antibiotic for Lungs Wins Approval". BusinessWeek. Diarsipkan dari versi asli tanggal 2 March 2010. Diakses tanggal 5 March 2010.
- "FDA approves Gilead cystic fibrosis drug Cayston". BusinessWeek. 23 February 2010. Diarsipkan dari versi asli tanggal 1 March 2010. Diakses tanggal 5 March 2010.
worldcat.org
- World Health Organization (2019). The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl:10665/330668 . ISBN 9789241210300. ISSN 0512-3054. WHO technical report series;1021.